Published online Apr 15, 2019. doi: 10.4251/wjgo.v11.i4.322
Peer-review started: November 19, 2018
First decision: December 7, 2018
Revised: January 3, 2019
Accepted: January 8, 2019
Article in press: January 9, 2019
Published online: April 15, 2019
Processing time: 147 Days and 5.8 Hours
Disease recurrence remains the chief reason for post-transplant mortality for hepatocellular carcinoma (HCC) patients. High risk patients should undergo close biochemical and radiological surveillance and start immunosuppressive agent with anti-tumor effect soon after the operation. A risk predictive model helps to implement this strategy selectively; however, the availability of such model is limited in the literature.
A more well-known validated model, the RETREAT score, had been popularized in Western Europe and North America. However, this model had not been validated in Asian populations where the prevalence of hepatitis B virus (HBV) infection is high. Therefore, another validated model that serves a complementary role to the RETREAT score has value.
This study aimed to derive and validate a predictive model using a database from a large transplant center.
All patients were randomly allocated to training and validation sets. Factors that predict HCC recurrence were identified using multivariate analysis. A risk score was assigned to each of these factors according to their corresponding odds ratio and then a scoring model was developed. The accuracy of this model was validated and compared with other scoring models using data in the validation set with receiver-operating characteristic curve.
This is the first scoring model derived and validated in an Asian population. It is also the first time to incorporate salvage liver transplantation (LT) as one of the variables in the predictive system. This new model compared favorably with the RETREAT score, which did not include salvage LT in the multivariate analysis.
We believe that salvage LT should be included in the predictive model for post-LT HCC recurrence. This new model could be an improvement for Asian populations where HBV infection is prevalent.
Patients who were classified as high risk of HCC recurrence should be given close biochemical and radiological surveillance to detect early recurrence. In addition, immunosuppressant with anti-tumor effect (i.e., m-TOR inhibitor) should be commenced after 1 mo together with the minimization of calcineurin inhibitor. Future multi-center external validation should be contemplated to define further its accuracy and role.